Related Experiment Video
Updated: Aug 23, 2025

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia
Published on: August 18, 2015
Implications of COVID-19 to Stroke Medicine: An Epidemiological and Pathophysiological Perspective
1Department of Medicine, University of Limerick, Limerick, Ireland.
Insights
Coronavirus 2019 (COVID-19) increases stroke risk, particularly ischemic stroke, due to inflammation. While COVID-19-related hemorrhagic stroke raises mortality, adenoviral vaccine-associated cerebral venous sinus thrombosis (CVST) risk is low and stroke rates are lower in vaccinated individuals.
Area of Science:
- Vascular Neurology
- Stroke Medicine
- Infectious Diseases
Background:
- Neurological complications of Coronavirus 2019 (COVID-19), including stroke, are increasingly documented.
- COVID-19 is linked to a hypercoagulable state and inflammation, heightening the risk of both ischemic and hemorrhagic stroke, even in younger populations.
- Hemorrhagic stroke in COVID-19 patients correlates with worse outcomes.
Approach:
- This review synthesizes current evidence on COVID-19-related ischemic and hemorrhagic stroke.
- It focuses on the epidemiology and inflammatory pathophysiology of stroke in the context of COVID-19.
- The review also addresses cerebral venous sinus thrombosis (CVST) in relation to COVID-19 and adenoviral vaccines.
Key Points:
- COVID-19 is associated with an elevated risk of ischemic stroke.
- Hemorrhagic stroke in COVID-19 patients is linked to increased morbidity and mortality.
- While adenoviral COVID-19 vaccines carry a small risk of cerebral venous sinus thrombosis (CVST), overall stroke prevalence appears lower in vaccinated versus unvaccinated COVID-19 patients.
Conclusions:
- COVID-19 significantly impacts cerebrovascular health, increasing stroke incidence and severity.
- Understanding the inflammatory mechanisms underlying COVID-19-related stroke is crucial for effective management.
- Vaccination strategies may mitigate some stroke risks associated with COVID-19, despite rare vaccine-specific complications.
Abstract:
The neurological complications of Coronavirus 2019 (COVID-19) including stroke have been documented in the recent literature. COVID-19-related inflammation is suggested to contribute to both a hypercoagulable state and haemorrhagic transformation, including in younger individuals. COVID-19 is associated with a heightened risk of ischaemic stroke. Haemorrhagic stroke in COVID-19 patients is associated with increased morbidity and mortality. Cerebral venous sinus thrombosis (CVST) accounts for <1% of stroke cases in the general population but has come to heightened public attention due to the increased risk associated with adenoviral COVID-19 vaccines. However, recent evidence suggests the prevalence of stroke is less in vaccinated individuals than in unvaccinated COVID-19 patients. This review evaluates the current evidence of COVID-19-related ischaemic and haemorrhagic stroke, with a focus on current epidemiology and inflammatory-linked pathophysiology in the field of vascular neurology and stroke medicine.
Related Concept Videos
Regulation of Stroke Volume
Preload refers to the degree of stretch on the heart before it contracts. It's analogous to the stretching of a rubber band; the more it's stretched, the more forcefully it snaps back. This concept is encapsulated in the Frank-Starling law of the...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Atherosclerosis IV: Nursing Management
Cardiac Output II: Effect of Stroke Volume on Cardiac Output
Preload
Preload refers to the initial elongation of the cardiac myocytes before contraction and is related to the volume of blood filling the heart at the end of diastole, or end-diastolic volume. The...
Coronary Artery Disease II: Pathophysiology

